Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-03-29Clinical Trial Update: Anti-Inflammatory Treatment of Schizophrenia [NA]
A completed clinical trial investigating an anti-inflammatory treatment for schizophrenia; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-03-29Clinical Trial Update: Integrated Metacognitive Therapy in First Episode Psychosis [NA]
A completed clinical trial evaluated Integrated Metacognitive Therapy for first-episode psychosis in conditions including schizophrenia, sch…
-
CLINICAL_TRIALS trial_result · 2018-03-29Clinical Trial Update: INCLUDE: Using Lived Experience to Improve Mental Health Diagnosis v1
This completed clinical trial evaluated the use of lived experience to improve mental health diagnosis. It covered conditions including depr…
-
FDA approval · 2018-03-27FDA Approved: ZYPREXA RELPREVV — Supplemental Application (H2-Pharma LLC)
The FDA approved a supplemental application for ZYPREXA RELPREVV (olanzapine pamoate) submitted by H2-Pharma LLC.
-
CLINICAL_TRIALS research · 2018-03-26Clinical Trial Update: Plantar Sensation, Balance, Risk of Falling and Gait in Patients With Schizophrenia [NA]
A completed clinical trial evaluating plantar sensation, balance, risk of falling, and gait in patients with schizophrenia.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-03-23Clinical Trial Update: Risperidone and Desipramine in Alcohol Use and Schizophrenia [Phase 2]
Phase 2 trial of risperidone and desipramine in patients with schizophrenia and alcohol use disorder has completed; results were posted in 2…
-
CLINICAL_TRIALS trial_result · 2018-03-22Clinical Trial Update: Evaluation and Validation of Social Cognition Battery to Characterize Schizophrenic Patients Functioning [NA]
A completed clinical trial evaluating and validating a social cognition battery to characterize functioning in patients with schizophrenia.
-
CLINICAL_TRIALS trial_result · 2018-03-22Clinical Trial Update: Normal and Abnormal ERP During ToM and Emotional Conflicts in Schizophrenia [NA]
A completed clinical trial investigated normal and abnormal event-related potentials during theory of mind tasks and emotional conflict proc…
-
CLINICAL_TRIALS trial_result · 2018-03-20Clinical Trial Update: An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia [Phase 2]
Phase 2 inpatient trial assessing PF-02545920 for acute exacerbation of schizophrenia; results were posted in 2018.
-
EMA withdrawal · 2018-03-19EMA Refused: Fanaptum (iloperidone) — Vanda Pharmaceuticals Ltd
The EMA refused the marketing authorization for Fanaptum (iloperidone) from Vanda Pharmaceuticals Ltd for schizophrenia.
-
CLINICAL_TRIALS trial_result · 2018-03-14Clinical Trial Update: Alcoholism and Schizophrenia: Effects of Clozapine [Phase 4]
A Phase 4 trial evaluating clozapine for patients with schizophrenia and alcohol use disorder was terminated.
-
CLINICAL_TRIALS withdrawal · 2018-03-13Clinical Trial Update: Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia [NA]
A clinical trial evaluating transcranial direct current stimulation for hallucinations in first-episode schizophrenia has been withdrawn fro…
-
CLINICAL_TRIALS trial_result · 2018-03-08Clinical Trial Update: Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH) [Phase 4]
Phase 4 clinical trial update on using agomelatine to treat depression in people with schizophrenia, with the study status showing completio…
-
CLINICAL_TRIALS trial_result · 2018-03-08Clinical Trial Update: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study [Phase 1]
Phase 1 study exploring cannabidiol as a novel-type antipsychotic with a focus on drug delivery and drug–drug interactions in schizophrenia.…
-
CLINICAL_TRIALS trial_result · 2018-03-07Clinical Trial Update: Improving Cognition in Schizophrenia Using tDCS [NA]
A UCLA-sponsored clinical trial investigated whether transcranial direct current stimulation could improve cognition in schizophrenia; resul…
-
CLINICAL_TRIALS trial_result · 2018-02-28Clinical Trial Update: Pharmacovigilance in Gerontopsychiatric Patients [Phase 3]
A Phase 3 pharmacovigilance trial in gerontopsychiatric patients has been terminated; the study focused on dementia and depression with rela…
-
CLINICAL_TRIALS trial_result · 2018-02-27Clinical Trial Update: SCIT Versus TAR for Outpatients With Schizophrenia [NA]
A completed clinical trial comparing SCIT versus TAR for outpatients with schizophrenia.
-
CLINICAL_TRIALS research · 2018-02-26Clinical Trial Update: Repetitive Transcranial Magnetic Stimulation for the Treatment of Negative Symptoms in Schizophrenia Patients. [NA]
This entry reports on a clinical trial evaluating repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms…
-
CLINICAL_TRIALS trial_result · 2018-02-14Clinical Trial Update: Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia [Phase 4]
A Phase 4 pilot trial evaluating valproate as an adjunctive treatment for Toxoplasma gondii infection in early course schizophrenia has been…
-
CLINICAL_TRIALS trial_result · 2018-02-06Clinical Trial Update: A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants [Phase 1]
Phase 1 trial update for TAK-831-1001 in healthy participants; the study was terminated with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-01-30Clinical Trial Update: Novel Smoking Cessation Drug for Schizophrenia [Phase 2]
Phase 2 trial update for a novel smoking cessation drug studied in schizophrenia, with completed status and posted results.
-
CLINICAL_TRIALS trial_result · 2018-01-30Clinical Trial Update: DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia [Phase 2]
Phase 2 clinical trial update for DAAOI-2 as add-on treatment in treatment-resistant schizophrenia completed.
-
FDA approval · 2018-01-25FDA Approved: ARISTADA — Supplemental Application (Alkermes, Inc.)
FDA approves a supplemental application for ARISTADA (aripiprazole lauroxil) submitted by Alkermes, Inc. The approval updates the drug's lab…
-
CLINICAL_TRIALS trial_result · 2018-01-23Clinical Trial Update: Biomarker Study of Acamprosate in Schizophrenia [Phase 4]
Phase 4 biomarker study investigating acamprosate in schizophrenia and schizoaffective disorder; completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-01-17Clinical Trial Update: Computerized Cognitive Training for Schizophrenia in Brazil [Phase 3]
Phase 3 clinical trial evaluating computerized cognitive training for schizophrenia in Brazil.